# Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

> clinical trial · VERIFIED · 2026-07-02

Status: RECRUITING · Sponsor: Merck Sharp & Dohme LLC · Condition: Non-small Cell Lung Cancer (NSCLC)

- Company: Merck Sharp & Dohme LLC
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06170788

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.